Keran E E, Barker K L
Endocrinology. 1976 Nov;99(5):1386-97. doi: 10.1210/endo-99-5-1386.
An organ culture technique, employing a totally defined medium, was developed, in which the levels of glucose-6-P dehydrogenase (G6PD) activity in uterine tissue from estradiol-treated ovariectomized mature rats continued to increase in vitro for 18 h at a rate similar to that seen in vivo. Uterine G6PD levels did not increase in vitro in tissues from estrogen-deprived rats even if estradiol (10(-6)m) was added in vitro, but the administration of estradiol (5 mug/rat) in vivo for as little as 2 min permitted G6PD levels to increase by 0.03 units/uterus (from 0.075 to 0.10, units/uterus) after the 18 h incubation. The maximum increase of 0.08 units/uterus (from 0.147 to 0.230 units/uterus) was seen in uteri from rats which were given estradiol 12 h prior to sacrigice. Tissues from animals given estradiol for greater than 30 h exhibit a net decrease in G6PD levels under the in vitro conditions. The in vitro increase in G6PD activity is inhibited by the addition of either actinomycin D (5 mug/ml), cycloheximide (5 mug/ml), or cordycepin (150 mug/ml), or by the intrauterine injection of actinomycin D (10 mug/rat). Intrauterine administration of cycloheximide (100 mug/rat) inhibited the in vivo increase in enzyme activity; however, the enzyme levels increased after placement of uterine tissues from these animals into organ culture. The removal of cycloheximide, which was added at the beginning of incubation after the 12th h, restores the ability of the tissues to increase the G3PD activity, and this restoration is not blocked by the addition of actinomycin D, suggesting that the mRNA activity for uterine G6PD accumulated during in vitro inhibition of protein synthesis by cycloheximide. The in vitro increase in uterine G6PD is due to an increase in immunologically identifiable G6PD protein and this increase is due, at least in part, to an increase in the de novo synthesis of the enzyme, as measured by the incorporation of [14C]leucine into immunochemically isolated G6PD protein. These results suggest that once initiated in vivo by estradiol, the uterus is capable of continuing in vitro those events, including the synthesis of both RNA and protein, which result in an increased rate of synthesis of uterine G6PD.
开发了一种使用完全限定培养基的器官培养技术,在该技术中,来自经雌二醇处理的去卵巢成熟大鼠子宫组织中的葡萄糖-6-磷酸脱氢酶(G6PD)活性水平在体外以与体内相似的速率持续增加18小时。即使在体外添加雌二醇(10^(-6)M),雌激素缺乏大鼠组织中的子宫G6PD水平在体外也不会增加,但是在体内给予雌二醇(5μg/大鼠)仅2分钟,在孵育18小时后,G6PD水平就会增加0.03单位/子宫(从0.075增加到0.10单位/子宫)。在处死前12小时给予雌二醇的大鼠子宫中,观察到最大增加量为0.08单位/子宫(从0.147增加到0.230单位/子宫)。在体外条件下,给予雌二醇超过30小时的动物组织中G6PD水平出现净下降。添加放线菌素D(5μg/ml)、环己酰亚胺(5μg/ml)或虫草素(150μg/ml),或子宫内注射放线菌素D(10μg/大鼠),均可抑制体外G6PD活性的增加。子宫内给予环己酰亚胺(100μg/大鼠)可抑制体内酶活性的增加;然而,将这些动物的子宫组织置于器官培养中后,酶水平会升高。在第12小时孵育开始时添加的环己酰亚胺去除后,组织增加G3PD活性的能力得以恢复,并且这种恢复不会被添加放线菌素D所阻断,这表明子宫G6PD的mRNA活性在体外被环己酰亚胺抑制蛋白质合成期间积累。子宫G6PD在体外的增加是由于免疫可识别的G6PD蛋白增加,并且这种增加至少部分是由于酶的从头合成增加,这通过将[14C]亮氨酸掺入免疫化学分离的G6PD蛋白中进行测定。这些结果表明,一旦在体内由雌二醇启动,子宫就能够在体外继续进行那些包括RNA和蛋白质合成在内的事件,这些事件导致子宫G6PD合成速率增加。